Gastrointestinal Hemorrhage, Gastrointestinal Ulcer, Non-variceal Upper Gastrointestinal Bleeding
Conditions
Keywords
bleeding, ulcer, hemorrhage, gastrointestinal diseases, digestive system disease, peptic ulcer, proton pump inhibitor
Brief summary
The aim of this study is to assess the current management strategies in a pan-European real-life setting to uncover the unmet need in this area: non-variceal gastrointestinal bleedings.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients admitted to the hospital or inpatients with an overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical/laboratory evidences of acute blood loss from the upper GI tract * Evidence that an upper GI endoscopy was performed * The complete medical record is available for study related hospitalization.
Exclusion criteria
* NA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe clinical outcomes associated with current strategies of endoscopic and pharmacological treatment in several European countries, in respect of bleeding continuation, rebleeding, surgery and in-hospital mortality | Up to 30 days after the episode (bleeding) |
Secondary
| Measure | Time frame |
|---|---|
| To describe clinical management and how this compares across countries and Hospital types | Up to 30 days after the episode (bleeding) |
| To assess predictive factors for clinical management strategies and predictive factors related to clinical outcomes | Up to 30 days after the episode (bleeding) |
| To assess health care resource consumption in patients admitted with non-variceal upper gastrointestinal bleeding and the main drivers | Up to 30 days after the episode (bleeding) |
Countries
Belgium, Greece, Italy, Norway, Portugal, Spain, Turkey (Türkiye)
Outcome results
None listed